A phase II study of SCH 54031 (peg interferon alpha-2b/PEG-intron) in subjects with interferon-refractory chronic myelogenous leukemia.

Trial Profile

A phase II study of SCH 54031 (peg interferon alpha-2b/PEG-intron) in subjects with interferon-refractory chronic myelogenous leukemia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2012

At a glance

  • Drugs Peginterferon alfa-2b (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jul 2009 Planned patient numbers changed from 30 to 1 as reported by ClinicalTrials.gov.
    • 21 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top